marqibo- vincristine sulfate kit
acrotech biopharma llc - vincristine sulfate (unii: t5iro3534a) (vincristine - unii:5j49q6b70f) - marqibo® is indicated for the treatment of adult patients with philadelphia chromosome negative (ph-) acute lymphoblastic leukemia (all) in second or greater relapse or whose disease has progressed following two or more anti leukemia therapies. this indication is approved under accelerated approval based on overall response rate [see clinical studies (14)]. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). marqibo is contraindicated in patients with demyelinating conditions, including charcot-marie-tooth syndrome. marqibo is contraindicated in patients with hypersensitivity to vincristine sulfate or any of the other components of marqibo (vincristine sulfate liposome injection). marqibo is contraindicated for intrathecal administration risk summary based on findings from nonclinical studies and its mechanism of action, marqibo can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1 ),
endometrin vaginal tablets 100 mg
ferring pharmaceuticals private limited - progesterone, micronized - tablet, effervescent - progesterone, micronized 100.0 mg
zactran 150mgml solution for injection for cattle sheep and pigs
agritech enterprise sdn. bhd. - gamithromycin -
penethaone
divasa-farmavic s.a. - penethamate hydriodide - penethamate hydriodide 994.7 g/kg - antibiotic
arquist 250 mikrogram/dos inhalationsspray, suspension
arquist 125 mikrogram/dos inhalationsspray, suspension
biobag 300 larven zur medizinischen anwendung
biobag 100 larven zur medizinischen anwendung
biobag 50 larven zur medizinischen anwendung